Hypereosinophilic Syndrome
📧 Sign up to get email alerts when something new happens for Hypereosinophilic Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-10-19EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH
The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.
-
EMA withdrawal · 2022-07-05EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf
EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…
-
EMA withdrawal · 2019-10-16EMA Withdrawn: Imatinib medac (imatinib) — Medac
The EMA has withdrawn Imatinib Medac (imatinib) from the market.
-
EMA withdrawal · 2009-07-29EMA Application withdrawn: Bosatria (Mepolizumab) — Glaxo Group Limited
The EMA withdrew the application for Bosatria (mepolizumab) by Glaxo Group Limited for hypereosinophilic syndrome.